Investment Analysts’ Recent Ratings Changes for Natera (NTRA)

A number of firms have modified their ratings and price targets on shares of Natera (NASDAQ: NTRA) recently:

• 8/13/2026 – Natera had its price target raised by Citigroup Inc. from $315.00 to $365.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Natera had its price target raised by Stephens from $305.00 to $350.00. They now have an “overweight” rating on the stock.
• 8/12/2026 – Natera had its price target raised by Guggenheim from $290.00 to $360.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Natera was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/12/2026 – Natera had its price target raised by Piper Sandler from $249.00 to $363.50. They now have an “overweight” rating on the stock.
• 8/10/2026 – Natera had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $355.00 price target on the stock.
• 8/7/2026 – Natera had its price target raised by TD Cowen from $325.00 to $340.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Natera had its price target raised by Royal Bank Of Canada from $275.00 to $350.00. They now have an “outperform” rating on the stock.
• 8/7/2026 – Natera was given a new $348.00 price target by Robert W. Baird.
• 8/7/2026 – Natera was given a new $375.00 price target by Canaccord Genuity Group Inc..
• 8/7/2026 – Natera had its price target raised by Wells Fargo & Company from $220.00 to $284.00. They now have an “equal weight” rating on the stock.
• 8/7/2026 – Natera had its price target raised by Citigroup Inc. from $300.00 to $315.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Natera had its price target raised by BTIG Research from $290.00 to $320.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Natera was given a new $330.00 price target by Leerink Partners.
• 8/7/2026 – Natera had its “overweight” rating reaffirmed by Barclays PLC. They now have a $340.00 price target on the stock.
• 8/7/2026 – Natera had its price target raised by JPMorgan Chase & Co. from $315.00 to $360.00. They now have an “overweight” rating on the stock.
• 7/17/2026 – Natera had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Natera had its “buy” rating reaffirmed by TD Cowen.
• 7/14/2026 – Natera was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/14/2026 – Natera had its price target raised by Canaccord Genuity Group Inc. from $285.00 to $330.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Natera had its price target raised by Morgan Stanley from $250.00 to $310.00. They now have an “overweight” rating on the stock.
• 7/6/2026 – Natera had its “outperform” rating reaffirmed by Evercore Inc. They now have a $300.00 price target on the stock.
• 6/29/2026 – Natera had its price target raised by Guggenheim from $270.00 to $290.00. They now have a “buy” rating on the stock.

Insider Transactions at Natera

In other news, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the completion of the transaction, the director directly owned 1,076,198 shares in the company, valued at $237,097,181.38. This trade represents a 6.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Solomon Moshkevich sold 3,410 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80. Following the sale, the insider directly owned 129,019 shares of the company’s stock, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 177,955 shares of company stock valued at $40,704,193. Corporate insiders own 5.05% of the company’s stock.

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.